|
1
|
DeLellis RA, Lloyd VR, Heitz PU and Eng C
(eds): World Health Organization Classification of Tumours:
Pathology and Genetics of Tumours of Endocrine Organs. IARC Press,
Lyon, 2004.
|
|
2
|
Sadow PM and Faquin WC: Poorly
differentiated thyroid carcinoma: An incubating entity. Front
Endocrinol (Lausanne). 3(77)2012.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tallini G: Poorly differentiated thyroid
carcinoma. Are we there yet? Endocr Pathol. 22:190–194.
2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Volante M, Collini P, Nikiforov YE,
Sakamoto A, Kakudo K, Katoh R, Lloyd RV, LiVolsi VA, Papotti M,
Sobrinho-Simoes M, et al: Poorly differentiated thyroid carcinoma:
The turin proposal for the use of uniform diagnostic criteria and
an algorithmic diagnostic approach. Am J Surg Pathol. 31:1256–1264.
2007.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Garcia-Rostan G and Sobrinho-Simões M:
Poorly differentiated thyroid carcinoma: An evolving entity.
Diagnostic Histopathol. 17:114–123. 2011.
|
|
6
|
Volante M and Papotti M: Poorly
differentiated thyroid carcinoma: 5 years after the 2004 WHO
classification of endocrine tumours. Endocr Pathol. 21:1–6.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Eloy C, Ferreira L, Salgado C, Soares P
and Sobrinho-Simões M: Poorly differentiated and undifferentiated
thyroid carcinomas. Turk Patoloji Derg. 31 (Suppl 1):S48–S59.
2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Omur O and Baran Y: An update on molecular
biology of thyroid cancers. Crit Rev Oncol Hematol. 90:233–252.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Walczyk A, Kowalska A and Sygut J: The
clinical course of poorly differentiated thyroid carcinoma (insular
carcinoma)-own observations. Endokrynol Pol. 61:467–473.
2010.PubMed/NCBI
|
|
10
|
Quiros RM, Ding HG, Gattuso P, Prinz RA
and Xu X: Evidence that one subset of anaplastic thyroid carcinomas
are derived from papillary carcinomas due to BRAF and p53
mutations. Cancer. 103:2261–2268. 2005.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Midgley CA and Lane DP: p53 protein
stability in tumour cells is not determined by mutation but is
dependent on Mdm2 binding. Oncogene. 15:1179–1189. 1997.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yemelyanova A, Vang R, Kshirsagar M, Lu D,
Marks MA, Shih IM and Kurman RJ: Immunohistochemical staining
patterns of p53 can serve as a surrogate marker for TP53 mutations
in ovarian carcinoma: An immunohistochemical and nucleotide
sequencing analysis. Mod Pathol. 24:1248–1253. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lam KY, Lo CY, Chan KW and Wan KY: Insular
and anaplastic carcinoma of the thyroid: A 45-year comparative
study at a single institution and a review of the significance of
p53 and p21. Ann Surg. 231(329)2000.PubMed/NCBI View Article : Google Scholar
|
|
15
|
McIver B, Hay ID, Giuffrida DF, Dvorak CE,
Grant CS, Thompson GB, van Heerden JA and Goellner JR: Anaplastic
thyroid carcinoma: A 50-year experience at a single institution.
Surgery. 130:1028–1034. 2001.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Penna GC, Vaisman F, Vaisman M,
Sobrinho-Simoes M and Soares P: Molecular markers involved in
tumorigenesis of thyroid carcinoma: Focus on aggressive histotypes.
Cytogenet Genome Res. 150:194–207. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Manzella L, Stella S, Pennisi MS, Tirro E,
Massimino M, Romano C, Puma A, Tavarelli M and Vigneri P: New
insights in thyroid cancer and p53 family proteins. Int J Mol Sci.
18(1325)2017.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Marcello MA, Morari EC, Cunha LL, De Nadai
Silva AC, Carraro DM, Carvalho AL, Soares FA, Vassallo J and Ward
LS: P53 and expression of immunological markers may identify early
stage thyroid tumors. Clin Dev Immunol. 2013(846584)2013.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shin MK, Kim JW, Min SK, Lee DJ, Kim JH,
Lee SC, Chung BW and Ju YS: Associations of the BRAF (V600E)
mutation and p53 protein expression with clinicopathological
features of papillary thyroid carcinomas patients. Oncol Lett.
10:1882–1888. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sanders EM Jr, LiVolsi VA, Brierley J,
Shin J and Randolph GW: An evidence-based review of poorly
differentiated thyroid cancer. World J Surg. 31:934–945.
2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Collini P, Mattavelli F, Pellegrinelli A,
Barisella M, Ferrari A and Massimino M: Papillary carcinoma of the
thyroid gland of childhood and adolescence: Morphologic subtypes,
biologic behavior and prognosis: A clinicopathologic study of 42
sporadic cases treated at a single institution during a 30-year
period. Am J Surg Pathol. 30:1420–1426. 2006.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hannallah J, Rose J and Guerrero MA:
Comprehensive literature review: Recent advances in diagnosing and
managing patients with poorly differentiated thyroid carcinoma. Int
J Endocrinol. 2013(317487)2013.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hashiba T, Maruno M, Fujimoto Y, Suzuki T,
Wada K, Isaka T, Izumoto S and Yoshimine T: Skull metastasis from
papillary thyroid carcinoma accompanied by neurofibromatosis type 1
and pheochromocytoma: Report of a case. Brain Tumor Pathol.
23:97–100. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kim BK, Choi YS, Gwoo S, Park YH, Yang SI
and Kim JH: Neurofibromatosis type 1 associated with papillary
thyroid carcinoma incidentally detected by thyroid ultrasonography:
A case report. J Med Case Rep. 6(179)2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Koksal Y, Sahin M, Koksal H, Esen H and
Sen M: Neurofibroma adjacent to the thyroid gland and a thyroid
papillary carcinoma in a patient with neurofibromatosis type 1:
Report of a case. Surg Today. 39:884–887. 2009.PubMed/NCBI View Article : Google Scholar
|
